Loading
Life sciences · Journal article
BMC Cancer · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Anti-PD-1 immunotherapy is a standard initial treatment for advanced non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression, yet its long-term benefit remains limited. Prior studies suggest that Yiqi Jiedu granules (YJG) provide clinical benefits in NSCLC. The study aimed to assess the long-term efficacy and safety of YJG in combination with first-line anti-PD-1 immunotherapy for advanced NSCLC and to explore potential associations. This randomized, double-blind, placebo-controlled trial enrolled 190 patients with PD-L1-high advanced NSCLC at Longhua Hospital from April 2021 to December 2023. Patients were randomized to receive anti-PD-1 therapy plus either YJG or placebo granules for a maximum of 35 cycles or until disease progression or intolerable toxicity. The primary endpoint was overall survival (OS). After a median follow-up of 25.7 months, YJG plus anti-PD-1 significantly prolonged OS compared to placebo plus anti-PD-1. The 2-year survival rates were 67.0% and 41.1%, respectively. Median progression-free survival (PFS) was longer in the YJG plus anti-PD-1 group than in the placebo group, although the difference was not statistically significant. Adverse events were comparable, and no grade 4–5 events occurred. Exploratory analyses showed that YJG plus anti-PD-1 was associated with lower IL-6 levels, higher peripheral CD8 + T-cell counts, and better quality of life at week 48. Metabolomic profiling further suggested nominally lower serum asparagine levels and potential alterations in tricarboxylic acid cycle-related metabolism. Adding YJG to first-line anti-PD-1 immunotherapy improved OS with favorable safety in PD-L1-high advanced NSCLC, supporting this combination as a promising adjunctive treatment. Registered on January 10, 2021 (registration number: ChiCTR2100041920).